4.4 Article

High frequency oscillations in the intra-operative ECoG to guide epilepsy surgery (The HFO Trial): study protocol for a randomized controlled trial

期刊

TRIALS
卷 16, 期 -, 页码 -

出版社

BMC
DOI: 10.1186/s13063-015-0932-6

关键词

Epilepsy surgery; Intra-operative electrocorticography; ECoG; Pediatric epilepsy; Epileptogenic zone; High frequency oscillations; HFOs; Randomized controlled trial

资金

  1. Dutch Epilepsy Foundation [2012-04]
  2. Rudolf Magnus Institute Talent Fellowship
  3. UMC Utrecht, The Netherlands

向作者/读者索取更多资源

Background: Intra-operative electrocorticography, based on interictal spikes and spike patterns, is performed to optimize delineation of the epileptogenic tissue during epilepsy surgery. High frequency oscillations (HFOs, 80-500 Hz) have been identified as more precise biomarkers for epileptogenic tissue. The aim of the trial is to determine prospectively if ioECoG-tailored surgery using HFOs, instead of interictal spikes, is feasible and will lead to an equal or better seizure outcome. Methods\Design: We present a single-blinded multi-center randomized controlled trial The HFO Trial including patients with refractory focal epilepsy of all ages who undergo surgery with intra-operative electrocorticography. Surgery is tailored by HFOs (arm 1) or interictal spikes (arm 2) in the intra-operative electrocorticography. Primary outcome is post-operative outcome after 1 year, dichotomized in seizure freedom (Engel 1A and 1B) versus seizure recurrence (Engel 1C-4). Secondary outcome measures are the volume of resected tissue, neurologic deficits, surgical duration and complications, cognition and quality of life. The trial has a non-inferiority design to test feasibility and at least equal performance in terms of surgical outcome. We aim to include 78 patients within 3 years including 1 year follow-up. Results are expected in 2018. Discussion: This trial provides a transition from observational research towards clinical interventions using HFOs. We address methodological difficulties in designing this trial. We expect that the use of HFOs as a biomarker for tailoring will increase the success rate of epilepsy surgery while reducing resection volume. This may reduce neurological deficits and yield a better quality of life. Future technical developments, such as validated automatic online HFO identification, could, together with the attained clinical knowledge, lead to a new objective tailoring approach in epilepsy surgery.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据